121
56.Conlon, K.C. Cytokines in the Treatment of Cancer / K.C. Conlon, M.D. Miljkovic, T.A. Waldmann // J. Interferon. Cytokine. Res. – 2019. – V. 39 (1). P. 6-21.
57.Costa, C. Methodology for the Isolation and Analysis of CTCs /C. Costa, A.B.
Dávila-Ibáñez // Adv. Exp. Med. Biol. - 2020. - V. 1220. - P. 45-59.
58.Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference / R.C. Jr. Bast, U.A. Matulonis, A.K. Sood et al. // Cancer. - 2019. - V. 125 (12). - P. 1963–1972.
59.Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance / A.B. Nagaraj, P. Joseph, O. Kovalenko et al. // Oncotarget. - 2015. - V. 6 (27). - P. 23720–23734.
60.CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs) / T. Tayoun, V. Faugeroux, M. Oulhen et al. // Cells. - 2019. - V. 8 (10). - P. 1145.
61.Cui, L. Expression of long non-coding RNA HOTAIR mRNA in ovarian cancer / L. Cui, X.Y. Xie, H. Wang // Sichuan Da XueXue Bao. Yi Xue Ban - Journal of Sichuan University. Medical Science Edition. - 2013. - V. 44 (1). - P. 57–59.
62.Cui, L. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis / L. Cui, J. Kwong, C.C. Wang // Journal of Ovarian Research. - 2015. - № 8. - P. 38.
63.Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles / M. Yousefi, S. Dehghani, R. Nosrati et al. // Cellular Oncology. - 2020. - V. 43 (4). - P. 515–538.
64.Dai, Q. LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway / Q. Dai, T. Zhang, C. Li // Cancer Management and Research. - 2020. - V. 12. - P. 1929–1939.
65.Dar, S. Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells / S. Dar, J. Chhina, I. Mert // Scientific Reports. - 2017. - V. 7 (1). - P. 8760.
66.De Smedt, L. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching / L. De Smedt, S. Palmans, D. Andel // British Journal of Cancer. 2017. - V. 116 (1). - P. 58-65.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
122
67.Decoding critical long non-coding RNA in ovarian cancer epithelial-to- mesenchymal transition / R. Mitra, X. Chen, E.J. Greenawalt et al. // Nature Communications. - 2017. - V. 8 (1). -P. 1604.
68.Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition / J. Yang, J. Ma, Y. Jin et al. // Scientific Reports. - 2021. - V. 11 (1). - P. 6540.
69.Dissimilar tumor cell populations in ascitic fluid of ovarian cancer patients / E.V. Kaigorodova, N.V.Fedulova, M.O.Ochirov et al. // Bulletin of Siberian Medicine. - 2020. - V. 19 (1). - P. 50-58.
70.Downregulated lincRNA HOTAIR expression in ovarian cancer stem cells decreases its tumorgeniesis and metastasis by inhibiting epithelial-mesenchymal transition / J. Wang, D. Chen, X. He et al. // Cancer Cell International. - 2015. - V. 15
(1). - P. 24.
71.Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients / J. Huo, J. Hu, G. Liu et al. // Archives of Gynecology and Obstetrics. - 2017. - V. 295 (2). - P. 459-465.
72.Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment / Z. Sun, S. Yang, Q. Zhou et al. // Molecular Cancer. - 2018. - V. 17
(1). - P. 82.
73.EMT and Dissemination Precede Pancreatic Tumor Formation / A.D. Rhim, E.T. Mirek, N.M. Aiello et al. // Cell. - 2012. - V. 148 (1–2). - P. 349-361.
74.EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice / A.P.Morel, G.W.Hinkal, C.Thomas et al. // PLoS Genetics. - 2012. - V. 8 (5). - P. e1002723.
75.EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer / A.M. Haslehurst, M. Koti, M. Dharsee et al. // BMC Cancer. - 2012. - V. 12 (1). - P. 91.
76.EMT: 2016 / M.A. Nieto, R.Y.Huang, R.A. Jackson, J.P. Thiery // Cell. - 2016. - V.
166(1). - P. 21-45.
123
77.EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy / I. Chebouti, S. Kasimir-Bauer, P. Buderath et al. // Oncotarget. - 2017. - V. 30 (8). - P. 48820-48831.
78. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells / T. Celià-Terrassa, O. Meca-Cortés, F. Mateo et al. // Journal of
Clinical Investigation. - 2012. - V. 122 (5). - P. 1849-1868.
79.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting posttherapeutic outcome of ovarian cancer / I. Chebouti, J.D. Kuhlmann, P. Buderath et al. // Oncotarget. - 2017. - V. 15 (8). - P. 24303-24313.
80.ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance / J.D. Kuhlmann, P. Wimberger, A. Bankfalvi et al. // Clinical Chemistry. - 2014. - V. 60 (10). -P. 1282-1289.
81.Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells / K. Nakamura, K. Sawada, Y. Kinose et al. // Molecular Cancer Research. - 2017. - V. 15 (1). - P. 78-92.
82.Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells / I. Kryczek, S. Liu, M. Roh et al. // International Journal of Cancer. - 2012. - V.
130(1). - P. 29–39.
83.Expression of CD133-1 and CD133-2 in ovarian cancer / G. Ferrandina, G. Bonanno, L. Pierelli et al. // International Journal of Gynecologic Cancer. - 2008. - V.
18(3). - P. 506-514.
84.Fang, L. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer / L. Fang, H. Wang, P. Li // Investigational New Drugs. - 2018. - V. 36 (2). - P. 187-194.
85.Ferlay, J. Global Cancer Observatory: Cancer Today / J. Ferlay. - Lyon, France: International Agency for Research on Cancer. 2018.
86.Fluids and their mechanics in tumour transit: shaping metastasis / G. Follain, D. Herrmann, S. Harlepp et al. // Nature Reviews Cancer. - 2020. - V. 20 (2). - P. 107-124.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
124
87.Fulawka, L. Cancer stem cells--the current status of an old concept: literature review and clinical approaches /L. Fulawka, P. Donizy, A. Halon // Biol Res. – 2014. - V. 47
(1). - P.66.
88.Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer / T.Z. Tan, Q.H. Miow, R.Y. Huang et al. // EMBO Molecular Medicine. - 2013. - V. 5 (7). - P. 10511066.
89.Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis / F. Vafaee, E.K. Colvin, S.C. Mok et al. // Scientific Reports. - 2017. - V. 7 (1). - P. 10374.
90.Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel / C. Blassl, J.D. Kuhlmann, A. Webers et al. // Molecular Oncology. - 2016. - V. 10 (7). - P. 1030–1042.
91.Genetic variants of lncRNA HOTAIR and risk of epithelial ovarian cancer among Chinese women / H. Wu, X. Shang, Y. Shi et al. // Oncotarget. 2016. - V. 7 (27). - P. 41047-41052.
92.Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer / E. Obermayr, D.C. Castillo-Tong, D.Pils et al. // Cancer Medicine. - 2016. - V. 5 (6). - P. 1074–1080.
93.Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to- Mesenchymal Transition? / L.M. da Fonseca, V.A. da Silva, L. Freire-de-Lima et al. // Frontiers in Oncology. - 2016. - №6. - P.158.
94.Gonzalez, D.M. Signaling mechanisms of the epithelial-mesenchymal transition / D.M. Gonzalez, D. Medici // Science Signaling. - 2014. - V. 7 (344). - P.re8.
95.Guidelines and definitions for research on epithelial–mesenchymal transition / J. Yang, P. Antin, G. Berx et al. // Nature Reviews Molecular Cell Biology. - 2020. - V.
21(6). - P. 341-352.
96.Gutschner, T. The hallmarks of cancer: A long non-coding RNA point of view / T. Gutschner, S. Diederichs // RNA Biology. - 2012. - V. 9 (6). - P. 703-719.
125
97.Hanahan, D. Hallmarks of Cancer: The Next Generation / D. Hanahan, R.A. Weinberg // Cell. - 2011. - V. 144 (5). - P. 646–674.
98.Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer / E.V. Kaigorodova, O.E. Savelieva, L.A.Tashireva et al. // Molecules. - 2018. - V. 23 (4). - P. 727.
99.HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer / A.E. Teschendorff, S.H. Lee, A. Jones et al. // Genome Medicine. - 2015. - V. 7 (1). - P. 108.
100.HOTAIR Interacting with MAPK1 Regulates Ovarian Cancer skov3 Cell Proliferation, Migration, and Invasion / T. Yiwei, H. Hua, G. Hui et al. // Medical Science Monitor. - 2015. - V. 21. - P. 1856–1863.
101.HOTAIR is a potential target for the treatment of cisplatin-resistant ovarian cancer / Y. Wang, H. Wang, T. Song et al. // Molecular Medicine Reports. - 2015. - V. 12 (2). - P. 2211–2216.
102.Hu, L. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant / L. Hu, C. McArthur, R.B. Jaffe // British Journal of Cancer. - 2010. - V. 102 (8). - P. 1276–1283.
103.Hudson, L.G. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression / L.G. Hudson, R. Zeineldin, M.S. Stack // Clinical & Experimental Metastasis. - 2008. - V. 25 (6). - P. 643–655.
104.Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells / L.Y. Bourguignon, K. Peyrollier, W. Xia, E. Gilad // Journal of Biological Chemistry. - 2008. - V. 25 (283). - P. 17635–17651.
105.Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α–ZEB1 axis / J.V. Joseph, S. Conroy, K. Pavlov et al. // Cancer Letters. - 2015. - V. 359 (1). - P. 107–116.
106.Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation / N. Kang, S.Y. Choi, B.N. Kim et al. // BMC Cancer. - 2019. - V. 19 (1). - P. 148.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
126
107.Ignatiadis, M. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility / M. Ignatiadis, M. Lee, S.S. Jeffrey // Clinical Cancer Research. - 2015. - V. 21 (21). - P. 4786–4800.
108.Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma / J. Akahiro, R. Konno, K. Ito et al. // International Journal of Clinical Oncology. - 2004. - V. 9 (1). - P. 42–46.
109.Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy /C. Qian, A. Worrede-Mahdi, F. Shen et al. // Molecular Cancer Research. - 2018. - V. 16 (12). - P. 1844–1854.
110.Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin / J.W. Po, A. Roohullah, D. Lynch et al. // Journal of Circulating Biomarkers. - 2018. - № 7. - P. 184945441878261.
111.In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel / N. Casagrande, C. Borghese, F. Agostini et al. // International Journal of Molecular Sciences. - 2021. - V.
22(6). - P. 3019.
112.Inflammation is a key contributor to ovarian cancer cell seeding / D. Jia, Y. Nagaoka, M. Katsumata, S. Orsulic // Scientific Reports. - 2018. - V. 8 (1). - P. 12394.
113.Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment / T.
Vilsmaier, B. Rack, A. König et al. // Anticancer Research. - 2016. - V. 36 (10). - P.
5227–5236.
114.Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer / P. Wimberger, M. Heubner, F. Otterbach et al. // Gynecologic Oncology. - 2007. - V. 107 (2). - P. 331–338.
115.Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression / J. Deng, X. Bai, X. Feng et al. // BMC Cancer. - 2019. - V. 19 (1). - P. 618.
127
116.Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer / M. Desbois, A.R. Udyavar, L. Ryner et al. // Nature Communications. - 2020. - V. 11 (1). - P. 5583.
117.Interleukin17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma / A. Aotsuka, Y. Matsumoto, T. Arimoto et al. // Cancer Science. - 2019. - V. 110 (10). - P. 3068–3078.
118.Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer / R. Almahmoudi, A. Salem, S. Murshid et al. // Cancers (Basel). – 2019. – V. 11 (5). P. 650.
119.Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors / A. Latifi, R.B. Luwor, M. Bilandzic et al. // PLoS ONE. - 2012. - V. 7 (10). - P. e46858.
120.Kalluri, R. The basics of epithelial-mesenchymal transition / R. Kalluri, R.A. Weinberg // Journal of Clinical Investigation. - 2009. - V.119, № 6. - P. 1420–1428. 121.Kiesslich, T. Epigenetic control of epithelial-mesenchymal-transition in human cancer / T. Kiesslich, M. Pichler, D. Neureiter // Molecular and Clinical Oncology. - 2013. - V. 1 (1). - P. 3–11.
122.Klein, C.A. Framework models of tumor dormancy from patient-derived observations / C.A. Klein // Current Opinion in Genetics & Development. - 2011. - V.
21(1). - P. 42-49.
123.Klymenko, Y. Heterogeneous Cadherin Expression and Multicellular Aggregate Dynamics in Ovarian Cancer Dissemination // Neoplasia. - 2017. - V. 19 (7). - P. 549–
563.
124. Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy / Y. Yu, X. Zhang, H. Tian et al. // Journal of B.U.ON.: official journal of the Balkan Union of Oncology. - 2018. - V. 23 (5). - P. 1396–1401.
125.Lheureux, S. Epithelial ovarian cancer: Evolution of management in the era of precision medicine / S. Lheureux, M. Braunstein, A.M.Oza // CA Cancer. J. Clin. - 2019. - V. 69 (4). - P.280-304.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
128
126.Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring / I. Martins, I.P. Ribeiro, J. Jorge et al. // Genes. 2021. - V. 12 (3) - P. 349.
127.Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer‟s Biomarkers / D. Fernández-Lázaro, J.L. García Hernández, A.C. García et al. // Diagnostics. - 2020. - V. 10 (4). - P. 215.
128.Liquid Biopsy for the Management of Patients with Colorectal Cancer /T. Yamada, A. Matsuda, M. Koizumi et al. // Digestion. - 2019. - V. 99 (1). - P. 39–45.
129.Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? / D.B. Asante, L. Calapre, M. Ziman, et al. // Cancer Lett. – 2020. – V.468.
– P.59-71.
130.Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer / N. Jiang, J. Pan, S. Fang et al. // ClinicaChimica Acta. - 2019. - V. 495. - P. 331–337.
131.Liu, E. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1 / E. Liu, Z. Liu, Y. Zhou // International Journal of Clinical and Experimental Pathology. - 2015. - V. 8 (4). - P. 3803–3810.
132.Liu, Y.X. Cao Characteristics and Significance of the Pre-metastatic Niche / Y. Liu, // Cancer Cell. - 2016. - V. 30 (5) - P. 668–681.
133.Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer / X.H. Liu, M. Sun, F.Q. Nie et al.// Molecular Cancer. - 2014. - V. 13 (1). - P. 92.
134.LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes / J. Yan, Y. Dang, S. Liu et al. // Tumor Biology. - 2016. - V. 37 (12). - P. 16345–16355.
135.lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression / M. Huang, H. Wang, X. Hu, X. Cao // OncoImmunology. - 2019. - V. 8 (1). - P. e1518628.
136.Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients / R. Liu, Y. Zeng, C.F. Zhouet al. // Scientific Reports. - 2017. - V. 7 (1). - P. 18.
129
137.Long Noncoding RNA MALAT1 Controls Cell Cycle Progression by Regulating the Expression of Oncogenic Transcription Factor B-MYB / V. Tripathi, Z. Shen, A. Chakraborty et al. // PLoS Genetics. - 2013. - V. 9 (3). - P. e1003368.
138.Long non-coding RNA PVT1-mediated miR-543/SERPINI1 axis plays a key role in the regulatory mechanism of ovarian cancer / C. Qu, C. Dai, Y. Guo et al. // Bioscience Reports. - 2020. - V. 40 (6). - P. BSR20200800.
139.Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets / D. Meseure, K. DrakAlsibai, A. Nicolas et al. // BioMed Research International. - 2015. - V. 2015. - P. 1–14.
140.LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model / S. Mehdi, E. Macdonald, K. Galpin et al. // International Journal of Molecular Sciences. - 2020. - V. 21 (14). - P. 4992.
141.Mader, S. Liquid Biopsy: Current Status and Future Perspectives / S. Mader, K. Pantel // Oncology Research and Treatment. - 2017. - V. 40 (7–8). -P. 404–408.
142.MALAT1 overexpression promotes the growth of colon cancer by repressing β- catenin degradation / X. Zheng, J. Ren, B. Peng et al. // Cellular Signalling. - 2020. - V.
73.- P. 109676.
143.MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway /X.S. Wu, X.A. Wang, W.G. Wu et al. // Cancer Biology & Therapy. - 2014. - V. 15 (6). - P. 806–814.
144.Marusyk, A. Intra-tumour heterogeneity: a looking glass for cancer? / A. Marusyk, V. Almendro, K. Polyak // Nature Reviews Cancer. - 2012. - V. 12 (5). - P. 323–334.
145.Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis / J. Xu, T. Zheng, W. Hong // Cellular Physiology and Biochemistry. - 2018. - V. 50 (1). - P. 214–232.
146.Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance / A.B. Alvero, R. Chen, H.H. Fu et al. // Cell Cycle. - 2009. - V. 8 (1). - P. 158-166.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
130
147.Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy / B. Aktas, S. Kasimir-Bauer, M. Heubner et al. // International Journal of Gynecological Cancer. - 2011. - V. 21 (5). - P. 822–830.
148.Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To- Mesenchymal-Transition and Tumor Cell Migration / C. Mayer, S. Darb-Esfahani, A.S. Meyer et al. // Journal of Cancer. - 2016. - V. 7 (5). - P. 546–554.
149.Neutrophils escort circulating tumour cells to enable cell cycle progression / B.M. Szczerba, F. Castro-Giner, M. Vetter et al. // Nature. - 2019. - V. 566 (7745). - P. 553–
557.
150.Neutrophils suppress tumor infiltrating T cells in colon cancer via matrix metalloproteinase mediated activation of TGFβ/ M. Germann, N. Zangger, M.O. Sauvain et al. // EMBO Molecular Medicine. - 2020. - V. 12 (1). -P. e10681
151.Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / J.A. Ledermann, F.A. Raja, C. Fotopoulou et al. // Ann Oncol. – 2013. – V.24, Suppl 6. - P.vi24-32.
152.NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH + Cancer Stem–like Cells / C.D. House, E. Jordan, L. Hernandez et al. // Cancer Research. - 2017. - V. 77 (24). - P. 6927–6940.
153.NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular
senescence in ovarian cancer / A.R. Özeş, D.F. Miller, O.N. Özeş et al. // Oncogene. - 2016. -V. 35 (41). - P. 5350–5361.
154. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer / A.
González-Martín, B. Pothuri, I. Vergote et al. // New England Journal of Medicine. - 2019. - V. 381 (25). - P. 2391–2402.
155.Nowell, P. The clonal evolution of tumor cell populations / P. Nowell // Science. 1976. - V. 194 (4260). - P.23-28.